GB Patent

GB2514285B — Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors

Assigned to Grindeks JSC · Expires 2018-07-18 · 8y expired

What this patent protects

Patent listed against nilotinib-hydrochloride.

Drugs covered by this patent

Patent Metadata

Patent number
GB2514285B
Jurisdiction
GB
Classification
—
Expires
2018-07-18
Drug substance claim
No
Drug product claim
No
Assignee
Grindeks JSC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.